Ph3 Study of Post-Neoadjuvant MK2870 in combo with Pembro (MK3475) with triple neg breast cancer

Phase III Clinical Trial

MK2870-012: A Phase 3 Randomized Open-label Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery

Indication: Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer
Trial Number: 06393374
Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations